Combining the greatest features of both CEX and DEX, DTX Exchange's (DTX) originality continues to be its major draw, making it the best ICO available. With its constant milestones, the DTX Exchange's ...

Zydus Lifesciences has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial testing its experimental oral treatment usnoflast in people with amyotrophic lateral ...

Zydus Lifesciences: The pharmaceutical company announced the USFDA orphan drug designation to Usnoflast for the treatment of amyotrophic lateral sclerosis. Agro Tech Foods: The CCI approved the ...

Zydus Lifesciences Ltd. said on Wednesday that the US Food and Drug Administration granted its underdevelopment drug Usnoflast the orphan drug designation, according to an exchange filing on Wednesday ...

“This Orphan Drug Designation from the USFDA underlines the urgent need to develop Usnoflast to address Amyotrophic Lateral Sclerosis (ALS), which is a fatal neurodegenerative disease," said Zydus' ...

which saw daily inflows of $2-$3 million before its ICO. This surge positions Wall Street Pepe for substantial gains, with the potential to deliver 7x to 10x returns once it launches on the market.

Zydus Life share price: Pharmaceutical company Zydus Life shares rose up to 1.93 per cent to hit an intraday high of Rs 1,013.35 per share on Monday, January 20, 2025. The rise in the Zydus Life share ...

One 97 Communications Paytm, Zomato, APL Apollo Tubes, Central Bank of India, Dixon Technologies, IDBI Bank, Indian Overseas Bank, Indian Railway Finance Corporation, ICICI Securities, Jammu ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and acquisitions, here’s a quick look at which stocks will be ...

Credit: David Herraez Calzada / Shutterstock. The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 ...

The trend is also visible in other FMCG companies. Zydus Wellness, the company behind brands like Complan and Glucon-D, is expanding its rural coverage, focusing on increasing penetration where brands ...